Atea Pharmaceuticals (NASDAQ:AVIR) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... [Yahoo! Finance]
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript [Seeking Alpha]
Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript [Seeking Alpha]